DeandreaS, MontanariM, MojaL, ApoloneG: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol, 2008; 19:1985–1991.
2.
DeerTR, SmithHS, BurtonAW, et al.: Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician, 2011; 14:E283–E312.
3.
DeerTR, PopeJE, HayekSM, et al.: The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation, 2017; 20:96–132.
4.
SmithTJ, CoynePJ, StaatsPS, et al.: An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol, 2005; 16:825–833.
